UnitedHealth Group (NYSE:UNH) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, December 7th.
A number of other equities analysts have also issued reports on the company. Cantor Fitzgerald raised their target price on UnitedHealth Group to $225.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 18th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $245.00 price target (up from $230.00) on shares of UnitedHealth Group in a research report on Wednesday, November 29th. Credit Suisse Group initiated coverage on UnitedHealth Group in a research report on Thursday, November 2nd. They set an “outperform” rating and a $233.00 price target on the stock. Royal Bank of Canada increased their price target on UnitedHealth Group to $244.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 29th. They noted that the move was a valuation call. Finally, UBS Group reaffirmed an “overweight” rating on shares of UnitedHealth Group in a research report on Thursday, August 24th. Three research analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $224.98.
Shares of UnitedHealth Group (UNH) traded up $0.70 during mid-day trading on Thursday, reaching $221.16. The company had a trading volume of 3,484,914 shares, compared to its average volume of 2,790,000. The stock has a market cap of $213,830.00, a price-to-earnings ratio of 25.13, a price-to-earnings-growth ratio of 1.64 and a beta of 0.66. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.70 and a quick ratio of 0.70. UnitedHealth Group has a one year low of $156.09 and a one year high of $231.77.
UnitedHealth Group (NYSE:UNH) last issued its earnings results on Tuesday, October 17th. The healthcare conglomerate reported $2.66 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.57 by $0.09. The company had revenue of $50.32 billion during the quarter, compared to analyst estimates of $50.38 billion. UnitedHealth Group had a return on equity of 21.52% and a net margin of 4.50%. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter last year, the business posted $2.17 EPS. equities analysts predict that UnitedHealth Group will post 9.99 earnings per share for the current year.
In other news, Director Michele J. Hooper sold 5,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $222.20, for a total transaction of $1,111,000.00. Following the sale, the director now directly owns 36,989 shares in the company, valued at approximately $8,218,955.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Larry C. Renfro sold 22,598 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $221.75, for a total value of $5,011,106.50. Following the sale, the chief executive officer now owns 195,314 shares in the company, valued at $43,310,879.50. The disclosure for this sale can be found here. Insiders have sold a total of 34,630 shares of company stock worth $7,669,416 over the last 90 days. Insiders own 0.89% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the stock. Prudential Financial Inc. boosted its holdings in UnitedHealth Group by 6.1% in the 3rd quarter. Prudential Financial Inc. now owns 2,560,731 shares of the healthcare conglomerate’s stock worth $501,520,000 after buying an additional 146,274 shares during the last quarter. Atlantic Trust Group LLC lifted its stake in UnitedHealth Group by 1.1% in the 3rd quarter. Atlantic Trust Group LLC now owns 1,002,906 shares of the healthcare conglomerate’s stock worth $196,418,000 after purchasing an additional 10,836 shares in the last quarter. AustralianSuper Pty Ltd purchased a new position in UnitedHealth Group in the 3rd quarter worth approximately $79,633,000. Parametric Portfolio Associates LLC lifted its stake in UnitedHealth Group by 4.2% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 3,655,449 shares of the healthcare conglomerate’s stock worth $715,920,000 after purchasing an additional 146,133 shares in the last quarter. Finally, Institutional & Family Asset Management LLC lifted its stake in UnitedHealth Group by 4.6% in the 3rd quarter. Institutional & Family Asset Management LLC now owns 19,346 shares of the healthcare conglomerate’s stock worth $3,789,000 after purchasing an additional 857 shares in the last quarter. Institutional investors own 86.01% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “UnitedHealth Group (NYSE:UNH) Stock Rating Lowered by ValuEngine” was reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.truebluetribune.com/2018/01/03/unitedhealth-group-unh-downgraded-by-valuengine.html.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.